Biomind Labs, Inc. is a biotech research and development company focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND02 ? N, N-dimethytryptamine that is in Phase II clinical trials for use in the treatment of depression; and BMND01 ? Ayahuasca, a product candidate in pre-clinical trials for use in the treatment of smoking addiction. Its product candidates in evaluation stage include BMND03 ? Psilocybin for treating chronic pain; BMND04 ? Mescaline for treating eating disorders and neurodegenerative diseases; and BMND05 ? 5-MeO-DMT, an anti-inflammatory product. The company was founded in 2021 and is headquartered in Toronto, Canada.